Impact of an educational program on efficacy and adherence with a twice-daily lamivudine/zidovudine/abacavir regimen in underrepresented HIV-infected patients

Journal of Acquired Immune Deficiency Syndromes

Volumn 34, Issue 2, 2003, Pages 174-183

  Rawlings, M Keith ^a,g   Thompson, Melanie A ^b   Farthing, Charles F ^c   Brown, Lawrence S ^d   Racine, Joseph ^e   Scott, Robert C ^h   Crawford, Karen H ^h   Goodwin, S Diane ^f   Tolson, Jerry M ^f   Williams, Vanessa C ^f   Shaefer, Mark S ^f  

^a Southeast Dallas Health Center   (United States)

^b AIDS Research Consortium of Atlanta   (United States)

^c AIDS Hlthcare Found Res Center   (United States)

^d Addiction Research and Treatment Corporation   (United States)

^e South Florida Reception Center   (United States)

^f GLAXOSMITHKLINE   (United States)

^g Intgd Minority AIDS Network Inc   (United States)

^h NONE

Author keywords

Abacavir; Adherence; Hypersensitivity reaction; Lamivudine; Underrepresented populations; Zidovudine

Indexed keywords

ABACAVIR; CD4 ANTIGEN; LAMIVUDINE PLUS ZIDOVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUNSELING; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; ETHNOLOGY; FATIGUE; FEMALE; HEALTH EDUCATION; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; LACTIC ACIDOSIS; LIVER TOXICITY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VERTIGO; VIRUS CONCENTRATION; VIRUS LOAD;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DIDEOXYNUCLEOSIDES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PATIENT EDUCATION; RNA, VIRAL; ZIDOVUDINE;

EID: 0141923763     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200310010-00007     Document Type: Article

References (32)

1. Gifford AL, Cunningham WE, Heslin KC, et al. Participation in research and access to experimental treatments by HIV-infected patients. N Engl J Med. 2002;346:1373-1382.
2. UNAIDS AIDS Epidemic Update, December 2000 AIDS Summary, No. 3 (Published: 2001.01):7 Available at: http://www.unaids.org/epidemic_update/report_DECOO/index_dec.html.
3. Centers for Disease Control and Prevention (CDC). HIV/AIDS Surveillance Report. 2003;13:144.
4. Association of State and Territorial Health Officials (ASTHO) Infectious Disease Policy Committee. ID-5. Injection drug use-related blood borne infection. Available at: http://www.astho.org/infectious/documents/hivaids/InjectionPolicy.pdf. Accessed January 10, 2002.
5. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med. 1999;131:81-87.
6. Singh N, Berman SM, Swindells S, et al. Adherence of human immunodeficiency virus-infected patients to antiretroviral therapy. Clin Infect Dis. 1999;29:824-830.
7. Singh N, Squire C, Swek C, et al. Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: prospective assessment with implications for enhancing compliance. AIDS Care. 1996;8:261-269.
8. Gifford AG, Bormann JE, Shively MJ, et al. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J Acquir Immune Defic Syndr. 2000;23:386-395.
9. Tuldrà A, Ferrer MJ, Rodriguez C, et al. A proposed model to predict compliance with antiretroviral therapy [abstract I-177]. Presented at the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, September 1998.
10. Lucas GM, Cheever LW, Chaisson RE, et al. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr. 2001;27:251-259.
11. Malow RM, Baker SM, Klimas N, et al. Adherence to complex combination antiretroviral therapies by HIV-positive drug abusers. Psychiatr Serv. 1998;49:1021-1022,1024.
12. Maisels L, Steinberg J, Toias C. An investigation of why eligible patients do not receive HAART. AIDS Patient Care STDs. 2001;15(Suppl): L185-L191.
13. Tuldrà A, Fumaz CR, Ferrer MJ, et al. Prospective randomized two-arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2000;25:221-228.
14. Cheever LW, Barnes GL, Chaisson RE. A randomized educational intervention to improve adherence with medication [abstract I-178]. Presented at the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, September 1998.
15. Kunches L, Mazzullo JM, Miller-Mack E, et al. Educational and support needs of people living with HIV (PLWH) to improve adherence to highly active antiretroviral therapy (HAART) [abstract 32333]. Presented at the 12th World AIDS Conference, Geneva, June-July 1998.
16. Staszewski S, Keiser P, Montaner J, et al. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naïve HIV-infected adults. A randomized equivalence trial. JAMA. 2001;285: 1155-1163.
17. Matheron S, Brun-Vezinet F, Katlama C, et al. 48-Week results of the CNAF 3007/Ecureuil open label study: efficacy and safety of the triple nucleoside combination Combivir/abacavir versus Combivir/nelfinavir as first line antiretroviral therapy in HIV-1 infected adults (abstract/poster 121]. Presented at the 5th International Congress on Drug Therapy in HIV Infection, Glasgow, October 2000.
18. Vibhagool A, on behalf of the CNA3014 International Study Team. Abacavir/Combivir (ABC/COM) is comparable to indinavir/Combivir (IDV/COM) in HIV-1-infected antiretroviral therapy naïve adults: results of a 48-week open-label study (CNA3014) [abstract/poster 063]. Presented at the 1st International AIDS Society (IAS) Conference on HIV Pathogenesis and Treatment, Buenos Aires, July 2001.
19. Igboko E, Scott-Lennox J, Pham DV, et al. Impact of T.H.E. course (Tools for Health and Empowerment) on medication adherence: pilot study [poster 14274]. Presented at the 12th World AIDS Conference, Geneva, June-July 1998.
20. Table for Grading of Adult Adverse Experiences. Washington, DC: National Institute of Allergy and Infectious Diseases, Division of AIDS; August 1992.
21. Rice MM, Hardy WD, Igboko EF, et al. Impact of T.H.E. (Tools for Health and Empowerment) COURSE on medication adherence: a pilot study [poster R13]. Presented at the 11th Annual Conference of the Association of Nurses in AIDS Care, San Antonio, November 1998.
22. Kalichman SC, Ramachandran B, Catz S. Adherence to combination antiretroviral therapies in HIV patients of low health literacy. J Gen Intern Med. 1999;14:267-273.
23. Del Rio C, Green S, Abrams C, et al. From diagnosis to undetectable: the reality of HIV/AIDS care in the inner city [abstract S21]. Presented at the 8th Conference on Retroviruses and Opportunistic Infections, Chicago, February 2001.
24. Gifford AL, Bormann JE, Shively MJ, et al. Effects of group HIV patient education on adherence to antiretrovirals: a randomized controlled trial [abstract 479]. Presented at the 8th Conference on Retroviruses and Opportunistic Infections, Chicago, February 2001.
25. Gulick RM, for the ACTG 5095 Team. Phase III, randomized, double-blind comparison of three protease inhibitor-sparing regimens for the initial treatment of HIV infection [oral presentation 41]. Presented at the 2nd IAS Conference on Pathogenesis and Treatment, Paris, July 2003.
26. Trizivir compared to efavirenz plus Combivir: 48 weeks interim study results from ACTG5095. March 10, 2003. Available at: www.natap. org/2003/march/031103_2.htm.
27. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21-30.
28. Wagner GJ. Predictors of antiretroviral adherence as measured by self-report, electronic monitoring, and medication diaries. AIDS Patient Care STDs. 2002;16:599-608.
29. Low-Beer S, Yip B, O'Shaughnessy MV, et al. Adherence to triple therapy and viral load response [letter]. J Acquir Immune Defic Syndr. 2000;23:360-361.
30. Hetherington S, McGuirk S, Powell G, et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther. 2001;23:1603-1614.
31. Symonds W, Cutrell A, Edwards M. Risk factor analysis of hypersensitivity reactions to abacavir. Clin Ther. 2002;24:565-573.
32. Loeliger AE, Steel H, McGuirk S, et al. The abacavir hypersensitivity reaction and interruptions in therapy [letter]. AIDS. 2001;15:1325.